- In June 2024, Merck announced significant advancements in its cancer drug development pipeline, including Phase II trials for tuvusertib (an ATR inhibitor) and M9466 (a PARP1 inhibitor). In addition, Merck progressed M9140 (anti-CEACAM5 ADC) and M3554 (novel anti-GD2 ADC) into clinical stages
- In June 2024, Eli Lilly reported positive results from an early-stage trial of olomorasib, a second-generation KRAS G12C inhibitor, which demonstrated efficacy against various solid tumors with KRAS G12C mutations, including non-small cell lung cancer. In this trial, olomorasib was combined with KEYTRUDA (pembrolizumab), a PD-1 inhibitor from Merck, which showed good tolerability when used together in another study
- In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced the FDA approval of LONSURF® (trifluridine/tipiracil) for the treatment of adults with metastatic colorectal cancer (mCRC). In addition, the approval followed prior treatments with anti-VEGF biological therapy, fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy, and, for RAS wild-type patients, an anti-EGFR therapy
- In June 2023, AstraZeneca and Daiichi Sankyo revealed positive results from the DESTINY CRC02 phase trial for Enhertu, showcasing both efficacy and safety in patients with HER-2 overexpressing metastatic colorectal cancer who had previously undergone treatment
- In June 2021, Bristol Myers Squibb received European Commission approval for the combination of Opdivo and Yervoy to treat anal cancer patients, granting marketing authorizations across Europe
